Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04677478 Not yet recruiting - Covid19 Clinical Trials

Impact of the Respiratory Isolation on the Quality of Life in Patients Hospitalized for Tuberculosis or COVID-19

ISO-BK
Start date: December 2020
Phase:
Study type: Observational

The respiratory isolation could have a harmful impact on the well-being of patients, especially in a psychological point of view such as anxiety and depression disorders or through the relationship with medical team and/or relatives but also in terms of informations. The evaluation of the impact of respiratory isolation in patients hospitalized for tuberculosis or COVID-19 could allow to identify the different kinds of problems encountered by these patients (physical, psychological, sociological, informations, ...) in order to adapt the environment for efficient care and to improve patient's well-being. The purpose of this research is to evaluate the psychological impact of the respiratory isolation on the quality of life in patients hospitalized for tuberculosis or COVID-19.

NCT ID: NCT04677283 Completed - Clinical trials for Symptoms Related to Covid-19

Study of Symptoms Linked to Covid-19 in Residents and Professionals in EHPAD, Associated With a Dual Diagnostic Approach by PCR and Serology: a Cohort in Île-de-France.

COVID - EHPAD
Start date: May 7, 2020
Phase:
Study type: Observational

The main purpose is to study the prevalence of Covid-19 in EHPAD. The primary endpoint will be the combination of PCR results and symptomatology, making it possible to define positive cases in EHPAD, in residents and professionals in contact with them. The prevalence obtained can be compared with the results of serology if these are performed.

NCT ID: NCT04676971 Completed - COVID-19 Clinical Trials

Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia

Start date: December 11, 2020
Phase: Phase 2
Study type: Interventional

Preliminarily investigate the safety and efficacy of two doses of hzVSF-v13 + SOC vs. placebo + SOC for the treatment of COVID-19 pneumonia.

NCT ID: NCT04676867 Completed - Covid19 Clinical Trials

Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

Start date: January 11, 2021
Phase: Phase 2
Study type: Interventional

This study is a placebo-controlled, Phase 2a proof-of-concept clinical study which will evaluate efficacy and safety of dalcetrapib in outpatients patients with mild to moderate, symptomatic, confirmed COVID 19.

NCT ID: NCT04675281 Completed - Covid19 Clinical Trials

Pathological Findings of Fatal COVID-19

HISTOCOVID
Start date: April 22, 2020
Phase:
Study type: Observational

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new coronavirus discovered in December 2019 in Wuhan, China and currently responsible of a worldwide outbreak and the death of more than 55,000 patients in France. The more severe form of COVID-19 disease induces a pneumonia with profound hypoxemia which may require invasive mechanical ventilation. It is estimated that 5% of COVID-19 patients are admitted to the Intensive Care Unit (ICU) for management. Hospital mortality in patients who develop severe acute respiratory distress syndrome (ARDS) ranges between 40% and 60%. The investigators purpose to investigate the pathological findings of COVID-19 patients who died from ARDS in the ICU by doing post-mortem lung biopsies

NCT ID: NCT04675086 Withdrawn - Covid19 Clinical Trials

Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection

Start date: January 2021
Phase: Phase 3
Study type: Interventional

This is a Randomized, Open-Label Study of the Efficacy and Safety of Aralast NP Infusion Therapy with Antiviral Treatment and standard of care versus Antiviral Treatment and standard of care (control group) in Hospitalized Patients with Pneumonia and COVID-19 Infection.

NCT ID: NCT04674644 Completed - COVID-19 Pandemic Clinical Trials

Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales

Start date: October 16, 2020
Phase: N/A
Study type: Interventional

The aims of this study were to (i) assess fear and anxiety of COVID-19 in a Turkish sample dental professionals using the Turkish FCV-19S and CAS; (ii) explore factors associated with FCV-19S and CAS; and (iii) examine the psychometric properties of the Turkish FCV-19S and CAS.

NCT ID: NCT04674566 Recruiting - Covid19 Clinical Trials

Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19

Start date: April 21, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Primary objectives Part 1: - To evaluate the safety and tolerability of COR-101 compared to placebo Secondary objectives Part 1: - To evaluate the preliminary efficacy of COR-101 compared to placebo in hospitalized patients with moderate to severe COVID-19 - To assess the pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of COR-101

NCT ID: NCT04674553 Completed - Obesity Clinical Trials

Effect of Obesity Among COVID-19 Patients in Critical Care Settings

Start date: November 10, 2020
Phase:
Study type: Observational

A novel human coronavirus that is now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (formerly called HCoV-19) emerged in Wuhan, China, in late 2019 and is now causing a pandemic. Human-to-human transmission is primarily achieved through close contact of respiratory droplets, direct contact with the infected individuals, or by contact with contaminated objects and surfaces. As a new chapter in human life opens up, the world seems to be divided into two parts pre- and post-COVID-19 era. Body mass index (BMI) is widely used to define obesity and overweight in adults. A BMI between 25 and 30 indicates overweight and above 30 indicates obesity. It is important to note that the levels of the inflammatory cytokines found in obese people are significantly higher than those in lean people, but they are still lower than those in individuals with infection or trauma. Obesity-mediated alterations in the airways and immune system are extremely important at the present moment considering SARS-Cov-2 infection. This study is designed to determine the effect of overweight and obesity with outcomes of patients with moderate to severe COVID-19 infection in critical care setting. Also, to see outcomes of assisted ventilation in obese patients. This may help in establishing strong association of obesity with COVID-19 in our part of the world. This may open new treatment strategies for COVID-19 by treating obesity as an essential risk factor.

NCT ID: NCT04674410 Withdrawn - Covid19 Clinical Trials

Utility of Empiric Antibiotics for Non-intubated Novel Coronavirus Diseases 2019 Patients

Start date: March 1, 2020
Phase:
Study type: Observational

This retrospective analysis of inpatient data obtained from administrative and electronic medical records will investigate the role of empiric antibiotics on admission on the mortality for non-intubated patients presenting with Novel Coronavirus Diseases 2019 (COVID-19) associated pneumonia without extra-pulmonary sources of infection or septic shock.